ChemicalBook > Product Catalog >API >Antineoplastic agents >Tinib Antineoplastic drugs >17,?19-?Metheno-?1H,?5H-?cyclopent[5,?6]?[1,?4]?oxazino[3,?4-?i]?pyrazolo[4,?3-?f]?pyrido[3,?2-?l]?[1,?4,?8,?10]?oxatriazacyclotridec?in-?14(11H)?-?one, 7-?fluoro-?2,?3,?3a,?12,?13,?20a-?hexahydro-?11-?methyl-?, (3aR,?11S,?20aS)?-

17,?19-?Metheno-?1H,?5H-?cyclopent[5,?6]?[1,?4]?oxazino[3,?4-?i]?pyrazolo[4,?3-?f]?pyrido[3,?2-?l]?[1,?4,?8,?10]?oxatriazacyclotridec?in-?14(11H)?-?one, 7-?fluoro-?2,?3,?3a,?12,?13,?20a-?hexahydro-?11-?methyl-?, (3aR,?11S,?20aS)?-

Request For Quotation
17,?19-?Metheno-?1H,?5H-?cyclopent[5,?6]?[1,?4]?oxazino[3,?4-?i]?pyrazolo[4,?3-?f]?pyrido[3,?2-?l]?[1,?4,?8,?10]?oxatriazacyclotridec?in-?14(11H)?-?one, 7-?fluoro-?2,?3,?3a,?12,?13,?20a-?hexahydro-?11-?methyl-?, (3aR,?11S,?20aS)?- Suppliers list
Company Name: ShangHai Caerulum Pharma Discovery Co., Ltd.  
Tel: 18149758185 18149758185
Email: sales-cpd@caerulumpharma.com
Company Name: Shanghai Chaolan Chemical Technology Center  
Tel: QQ：65489617 13301690235
Email: Sales@ATKchemical.com
Company Name: Shanghai SuperLan Chemcial Technique Centre  
Tel: 0-2022843681 15618226720
Email: chaolaichem@foxmail.com
Company Name: Kaixin Chemical (Hong Kong) Limited  
Tel: 010-88886666-01 13112345678
Email: loyson@qq.com
Company Name: Perida Pharmaceutical Co., Ltd.  
Tel: 010-87568995 13439954790;15011125736
Email: 2539095144@qq.com

17,?19-?Metheno-?1H,?5H-?cyclopent[5,?6]?[1,?4]?oxazino[3,?4-?i]?pyrazolo[4,?3-?f]?pyrido[3,?2-?l]?[1,?4,?8,?10]?oxatriazacyclotridec?in-?14(11H)?-?one, 7-?fluoro-?2,?3,?3a,?12,?13,?20a-?hexahydro-?11-?methyl-?, (3aR,?11S,?20aS)?- manufacturers

  • Enbezotinib
  • Enbezotinib pictures
  • $74.00
  • 2026-04-21
  • CAS:2359649-81-1
  • Purity: 99.84%
  • Supply Ability: 10g
17,?19-?Metheno-?1H,?5H-?cyclopent[5,?6]?[1,?4]?oxazino[3,?4-?i]?pyrazolo[4,?3-?f]?pyrido[3,?2-?l]?[1,?4,?8,?10]?oxatriazacyclotridec?in-?14(11H)?-?one, 7-?fluoro-?2,?3,?3a,?12,?13,?20a-?hexahydro-?11-?methyl-?, (3aR,?11S,?20aS)?- Basic information
Product Name:17,?19-?Metheno-?1H,?5H-?cyclopent[5,?6]?[1,?4]?oxazino[3,?4-?i]?pyrazolo[4,?3-?f]?pyrido[3,?2-?l]?[1,?4,?8,?10]?oxatriazacyclotridec?in-?14(11H)?-?one, 7-?fluoro-?2,?3,?3a,?12,?13,?20a-?hexahydro-?11-?methyl-?, (3aR,?11S,?20aS)?-
Synonyms:17,19-Metheno-1H,5H-cyclopent[5,6][1,4]oxazino[3,4-i]pyrazolo[4,3-f]pyrido[3,2-l][1,4,8,10]oxatriazacyclotridecin-14(11H)-one, 7-fluoro-2,3,3a,12,13,20a-hexahydro-11-methyl-, (3aR,11S,20aS)-;(13E,14E,15aR,18aS,5S)-35-fluoro-5-methyl-15,15a,16,17,18,18a-hexahydro-4-oxa-7-aza-1(5,3)-cyclopenta[b]pyrazolo[1',5':1,2]pyrimido[4,5-e][1,4]oxazina-3(3,2)-pyridinacyclooctaphan-8-one;Enbezotinib, 10 mM in DMSO;Enbezotinib，TPX-0046;Enbezotinib;(3aR,11S,20aS)-7-Fluoro-2,3,3a,12,13,20a-hexahydro-11-methyl-17,19-metheno-1H,5H-cyclopent[5,6][1,4]oxazino[3,4-i]pyrazolo[4,3-f]pyrido[3,2-l][1,4,8,10]oxatriazacyclotridecin-14(11H)-one (ACI)
CAS:2359649-81-1
MF:C21H21FN6O3
MW:424.43
EINECS:
Product Categories:
Mol File:2359649-81-1.mol
17,?19-?Metheno-?1H,?5H-?cyclopent[5,?6]?[1,?4]?oxazino[3,?4-?i]?pyrazolo[4,?3-?f]?pyrido[3,?2-?l]?[1,?4,?8,?10]?oxatriazacyclotridec?in-?14(11H)?-?one, 7-?fluoro-?2,?3,?3a,?12,?13,?20a-?hexahydro-?11-?methyl-?, (3aR,?11S,?20aS)?- Structure
17,?19-?Metheno-?1H,?5H-?cyclopent[5,?6]?[1,?4]?oxazino[3,?4-?i]?pyrazolo[4,?3-?f]?pyrido[3,?2-?l]?[1,?4,?8,?10]?oxatriazacyclotridec?in-?14(11H)?-?one, 7-?fluoro-?2,?3,?3a,?12,?13,?20a-?hexahydro-?11-?methyl-?, (3aR,?11S,?20aS)?- Chemical Properties
density 1.68±0.1 g/cm3(Predicted)
storage temp. Store at -20°C
solubility DMSO : 100 mg/mL (235.61 mM; ultrasonic and warming and heat to 80°C)
pka10.44±0.40(Predicted)
form Solid
color White to off-white
Safety Information
MSDS Information
17,?19-?Metheno-?1H,?5H-?cyclopent[5,?6]?[1,?4]?oxazino[3,?4-?i]?pyrazolo[4,?3-?f]?pyrido[3,?2-?l]?[1,?4,?8,?10]?oxatriazacyclotridec?in-?14(11H)?-?one, 7-?fluoro-?2,?3,?3a,?12,?13,?20a-?hexahydro-?11-?methyl-?, (3aR,?11S,?20aS)?- Usage And Synthesis
UsesEnbezotinib, an inhibitor of RET, can inhibit the RET autophosphorylation. Enbezotinib can be used for the research of cancer[1].
in vivo

Enbezotinib (compound 5) (2-5 mg/kg; twice daily for 27 days) decreases tumor size in mice[1].

References[1] ROGERS EW, et, al. Macrocyclic compounds for treating disease. WO2019126121A1.
17,?19-?Metheno-?1H,?5H-?cyclopent[5,?6]?[1,?4]?oxazino[3,?4-?i]?pyrazolo[4,?3-?f]?pyrido[3,?2-?l]?[1,?4,?8,?10]?oxatriazacyclotridec?in-?14(11H)?-?one, 7-?fluoro-?2,?3,?3a,?12,?13,?20a-?hexahydro-?11-?methyl-?, (3aR,?11S,?20aS)?- Preparation Products And Raw materials
Tag:17,?19-?Metheno-?1H,?5H-?cyclopent[5,?6]?[1,?4]?oxazino[3,?4-?i]?pyrazolo[4,?3-?f]?pyrido[3,?2-?l]?[1,?4,?8,?10]?oxatriazacyclotridec?in-?14(11H)?-?one, 7-?fluoro-?2,?3,?3a,?12,?13,?20a-?hexahydro-?11-?methyl-?, (3aR,?11S,?20aS)?-(2359649-81-1) Related Product Information
17,19-Metheno-1H,5H-cyclopent[5,6][1,4]oxazino[3,4-i]pyrazolo[4,3-f]pyrido[3,2-l][1,4,8,10]oxatriazacyclotridecin-14(11H)-one, 7-fluoro-2,3,3a,12,13,20a-hexahydro-11-methyl-, (3aS,11R,20aR)- 18,1-Metheno-6H-[1,4]oxazino[3,4-i]pyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-15(12H)-one, 9-fluoro-3,4,13,14-tetrahydro-4,13,13-trimethyl-, (4R)- 4H-1,16-Etheno-6,8-methanopyrazolo[3,4-h]pyrido[2,3-b][1,5,7,11]oxatriazacyclotetradecin-4-one, 12-fluoro-5,6,7,8,14,15-hexahydro-14-methyl-, (6α,8α,14R)- 18,1-Metheno-6H-[1,4]oxazino[3,4-i]pyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-15(12H)-one, 9-fluoro-3,4,13,14-tetrahydro-4,12-dimethyl-, (4R,12S)- Spiro[cyclopropane-1,11′-[11H-16,18]etheno[10H][1,4]oxazino[4,3-j]pyrazolo[4,3-f]pyrido[3,2-l][1,4,8,10]oxatriazacyclotridecin]-13′(12′H)-one, 6′-fluoro-1′,2′,4′,4′a-tetrahydro-, (4′aS)- 17,?19-?Metheno-?1H,?5H-?cyclopent[5,?6]?[1,?4]?oxazino[3,?4-?i]?pyrazolo[4,?3-?f]?pyrido[3,?2-?l]?[1,?4,?8,?10]?oxatriazacyclotridec?in-?14(11H)?-?one, 7-?fluoro-?2,?3,?3a,?12,?13,?20a-?hexahydro-?11-?methyl-?, (3aR,?11S,?20aS)?-